
Lawrence H Price

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10741672/publications.pdf Version: 2024-02-01



LANDENCE H PRICE

#	Article	IF	CITATIONS
1	Stakeholder perspectives on adjunctive mHealth services during transitions of care for patients with schizophrenia-spectrum disorders. Journal of Mental Health, 2022, , 1-7.	1.0	0
2	Molecular markers of neuroendocrine function and mitochondrial biogenesis associated with early life stress. Psychoneuroendocrinology, 2020, 116, 104632.	1.3	15
3	Development and Psychometric Evaluation of the Children's Yale-Brown Obsessive-Compulsive Scale Second Edition. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, 92-98.	0.3	29
4	The effects of early life stress on reward processing. Journal of Psychiatric Research, 2018, 101, 80-103.	1.5	129
5	Alterations of Mitochondrial DNA Copy Number and Telomere Length With Early Adversity and Psychopathology. Biological Psychiatry, 2016, 79, 78-86.	0.7	207
6	Editorial: Reporting guidelines for psychopharmacology. Psychopharmacology, 2016, 233, 1131-1134.	1.5	3
7	A Randomized Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant Depression. Biological Psychiatry, 2015, 78, 240-248.	0.7	415
8	Telomeres, Early-Life Stress and Mental Illness. Advances in Psychosomatic Medicine, 2015, 34, 92-108.	2.2	40
9	Interleukin 1B gene (<i>IL1B</i>) variation and internalizing symptoms in maltreated preschoolers. Development and Psychopathology, 2014, 26, 1277-1287.	1.4	23
10	Regional homogeneity and resting state functional connectivity: Associations with exposure to early life stress. Psychiatry Research - Neuroimaging, 2013, 214, 247-253.	0.9	46
11	Telomeres and Early-Life Stress: An Overview. Biological Psychiatry, 2013, 73, 15-23.	0.7	308
12	The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development. Scientific World Journal, The, 2012, 2012, 1-7.	0.8	39
13	Childhood Adversity and Epigenetic Modulation of the Leukocyte Glucocorticoid Receptor: Preliminary Findings in Healthy Adults. PLoS ONE, 2012, 7, e30148.	1.1	416
14	Effect of childhood physical abuse on cortisol stress response. Psychopharmacology, 2011, 214, 367-375.	1.5	257
15	Gene–environment interactions: early life stress and risk for depressive and anxiety disorders. Psychopharmacology, 2011, 214, 175-196.	1.5	213
16	Early life stress and psychopharmacology. Psychopharmacology, 2011, 214, 1-3.	1.5	4
17	A placebo-controlled study of sertraline's effect on cortisol response to the dexamethasone/corticotropin-releasing hormone test in healthy adults. Psychopharmacology, 2011, 218, 371-379.	1.5	6
18	Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature. Psychopharmacology, 2010, 212, 1-12.	1.5	154

#	Article	IF	CITATIONS
19	Childhood Maltreatment and Telomere Shortening: Preliminary Support for an Effect of Early Stress on Cellular Aging. Biological Psychiatry, 2010, 67, 531-534.	0.7	300
20	In Reply to: Childhood Maltreatment and Hypothalamic-Pituitary-Adrenal Axis Reactivity. Biological Psychiatry, 2010, 67, e61-e62.	0.7	0
21	The Clinical Correlates of Reported Childhood Sexual Abuse: An Association Between Age at Trauma Onset and Severity of Depression and PTSD in Adults. Journal of Child Sexual Abuse, 2010, 19, 156-170.	0.7	121
22	Association between Plasma IL-6 Response to Acute Stress and Early-Life Adversity in Healthy Adults. Neuropsychopharmacology, 2010, 35, 2617-2623.	2.8	378
23	Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opinion on Pharmacotherapy, 2010, 11, 709-722.	0.9	57
24	Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls. Psychoneuroendocrinology, 2009, 34, 1208-1213.	1.3	63
25	Childhood maltreatment and adult personality disorder symptoms: Influence of maltreatment type. Psychiatry Research, 2009, 165, 281-287.	1.7	125
26	Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression. Biological Psychiatry, 2009, 65, 267-275.	0.7	792
27	Effect of Childhood Emotional Abuse and Age on Cortisol Responsivity in Adulthood. Biological Psychiatry, 2009, 66, 69-75.	0.7	233
28	Interaction of Childhood Maltreatment with the Corticotropin-Releasing Hormone Receptor Gene: Effects on Hypothalamic-Pituitary-Adrenal Axis Reactivity. Biological Psychiatry, 2009, 66, 681-685.	0.7	254
29	Varenicline Augmentation in Depressed Smokers. Journal of Clinical Psychiatry, 2009, 70, 1026-1031.	1.1	77
30	Childhood Parental Loss and Adult Hypothalamic-Pituitary-Adrenal Function. Biological Psychiatry, 2008, 63, 1147-1154.	0.7	221
31	Sex differences in emotional and physiological responses to the Trier Social Stress Test. Journal of Behavior Therapy and Experimental Psychiatry, 2008, 39, 87-98.	0.6	258
32	Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Psychiatry Research, 2008, 157, 123-129.	1.7	14
33	Cortisol and ACTH responses to the Dex/CRH Test: Influence of temperament. Hormones and Behavior, 2008, 53, 518-525.	1.0	60
34	Childhood Parental Loss and Adult Psychopathology: Effects of Loss Characteristics and Contextual Factors. International Journal of Psychiatry in Medicine, 2008, 38, 329-344.	0.8	58
35	The Relationship Between Childhood Abuse and Adult Personality Disorder Symptoms. Journal of Personality Disorders, 2007, 21, 442-447.	0.8	84
36	Decreased Adrenocorticotropic Hormone and Cortisol Responses to Stress in Healthy Adults Reporting Significant Childhood Maltreatment. Biological Psychiatry, 2007, 62, 1080-1087.	0.7	458

#	Article	IF	CITATIONS
37	Psychotic Major Depression. Drug Safety, 2006, 29, 491-508.	1.4	22
38	Temperament and hypothalamic–pituitary–adrenal axis function in healthy adults. Psychoneuroendocrinology, 2006, 31, 1036-1045.	1.3	65
39	Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. American Journal of Psychiatry, 2006, 163, 637-43.	4.0	83
40	Cerebrospinal Fluid Corticotropin-Releasing Factor and Perceived Early-Life Stress in Depressed Patients and Healthy Control Subjects. Neuropsychopharmacology, 2004, 29, 777-784.	2.8	180
41	Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biological Psychiatry, 2004, 55, 296-300.	0.7	171
42	Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients. Biological Psychiatry, 2004, 56, 418-426.	0.7	103
43	Increased cerebrospinal fluid corticotropin-releasing factor concentrations during tryptophan depletion in healthy adults. Biological Psychiatry, 2004, 56, 531-534.	0.7	22
44	Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues. Neurosurgery Clinics of North America, 2003, 14, 199-212.	0.8	284
45	Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders. Neuropsychopharmacology, 2003, 28, 402-412.	2.8	233
46	Acute changes in Cerebrospinal Fluid 5-HIAA following Oral Paroxetine Challenge in Healthy Humans. Neuropsychopharmacology, 2003, 28, 339-347.	2.8	29
47	Update on stress and depression: the role of the hypothalamic-pituitary-adrenal (HPA) axis. Revista Brasileira De Psiquiatria, 2003, 25, 231-238.	0.9	117
48	A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine. Biological Psychiatry, 2002, 51, 183-188.	0.7	232
49	Drug combination strategies. , 2001, , 194-222.		6
50	Efficacy of Continuation ECT and Antidepressant Drugs Compared to Long-Term Antidepressants Alone in Depressed Patients. American Journal of Psychiatry, 2000, 157, 1960-1965.	4.0	134
51	A Double-blind, Placebo-Controlled Study of Risperidone Addition in Serotonin Reuptake Inhibitor–Refractory Obsessive-compulsive Disorder. Archives of General Psychiatry, 2000, 57, 794.	13.8	516
52	Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology, 1999, 24, 1-24.	1.3	88
53	Effects of the CCKB antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Research, 1999, 85, 225-240.	1.7	22
54	Mirtazapine Augmentation in the Treatment of Refractory Depression. Journal of Clinical Psychiatry, 1999, 60, 45-49.	1.1	149

#	Article	IF	CITATIONS
55	Tryptophan Depletion During Continuous CSF Sampling in Healthy Human Subjects. Neuropsychopharmacology, 1998, 19, 26-35.	2.8	270
56	A Double-blind, Placebo-Controlled Study of Risperidone in Adults With Autistic Disorder and Other Pervasive Developmental Disorders. Archives of General Psychiatry, 1998, 55, 633.	13.8	356
57	Clomipramine in Adults with Pervasive Developmental Disorders: A Prospective Open-Label Investigation. Journal of Child and Adolescent Psychopharmacology, 1997, 7, 109-121.	0.7	94
58	Assessment of diurnal variation of cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in healthy human females. Life Sciences, 1997, 60, 899-907.	2.0	16
59	Effects of Acute Tryptophan Depletion in Lithium-Remitted Manic Patients: A Pilot Study. Biological Psychiatry, 1997, 42, 1076-1078.	0.7	29
60	Effects of Antiglucocorticoid Treatment on 5-HT1A Function in Depressed Patients and Healthy Subjects. Neuropsychopharmacology, 1997, 17, 246-257.	2.8	19
61	Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. American Journal of Medical Genetics Part A, 1997, 74, 497-500.	2.4	24
62	Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. , 1997, 74, 497.		1
63	Intranasal oxytocin in obsessive-compulsive disorder. Biological Psychiatry, 1996, 40, 547-549.	0.7	81
64	OBSESSIVE-COMPULSIVE SYMPTOMS WITH NEUROLEPTICS. Journal of the American Academy of Child and Adolescent Psychiatry, 1996, 35, 837.	0.3	10
65	A Risk-Benefit Assessment of Drugs Used in the Management of Obsessive-Compulsive Disorder. Drug Safety, 1996, 15, 116-134.	1.4	15
66	Antiglucocorticoids as Treatments for Depression. CNS Drugs, 1996, 5, 311-320.	2.7	22
67	Cerebrospinal Fluid Biogenic Amines in Obsessive Compulsive Disorder, Tourette's Syndrome, and Healthy Controls. Neuropsychopharmacology, 1995, 12, 73-86.	2.8	150
68	Lithium or Desipramine Augmentation of Fluoxetine Treatment. American Journal of Psychiatry, 1995, 152, 1538-a-1539.	4.0	6
69	Serotonergic mechanisms of cocaine effects in humans. Psychopharmacology, 1995, 119, 179-185.	1.5	89
70	Effects of tryptophan depletion on responses to yohimbine in healthy human subjects. Biological Psychiatry, 1995, 38, 74-85.	0.7	44
71	m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: Absence of symptom exacerbation. Biological Psychiatry, 1995, 38, 138-149.	0.7	68
72	Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease. Biological Psychiatry, 1995, 38, 498-505.	0.7	23

#	Article	IF	CITATIONS
73	Lithium in the Treatment of Mood Disorders. New England Journal of Medicine, 1994, 331, 591-598.	13.9	240
74	Obsessive–Compulsive Disorder with and without a Chronic Tic Disorder. British Journal of Psychiatry, 1994, 164, 469-473.	1.7	210
75	Concurrent cocaine-ethanol ingestion in humans: pharmacology, physiology, behavior, and the role of cocaethylene. Psychopharmacology, 1993, 111, 39-46.	1.5	179
76	The Psychopharmacology of Obsessive Compulsive Disorder: Implications for Treatment and Pathogenesis. Psychiatric Clinics of North America, 1993, 16, 749-766.	0.7	63
77	Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease. New England Journal of Medicine, 1992, 327, 1541-1548.	13.9	569
78	Clomipramine in Autism: Preliminary Evidence of Efficacy. Journal of the American Academy of Child and Adolescent Psychiatry, 1992, 31, 746-750.	0.3	144
79	Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Use: Effects on Mood and Neuropsychological Function?. American Journal of Drug and Alcohol Abuse, 1992, 18, 331-341.	1.1	141
80	Serotonergic function during lithium augmentation of refractory depression. Psychopharmacology, 1992, 108, 93-97.	1.5	23
81	A comparison of trazodone and fluoxetine: implications for a serotonergic mechanis of antidepressant action. Psychopharmacology, 1992, 109, 2-11.	1.5	110
82	Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Research, 1991, 38, 227-236.	1.7	98
83	A Controlled Trial of Lithium Augmentation in Fluvoxamine-Refractory Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology, 1991, 11, 175???184.	0.7	120
84	Lithium and serotonin function: implications for the serotonin hypothesis of depression. Psychopharmacology, 1990, 100, 3-12.	1.5	151
85	Fluvoxamine/Pimozide Treatment of Concurrent Tourette's and Obsessive-Compulsive Disorder. British Journal of Psychiatry, 1990, 157, 762-765.	1.7	80
86	Clinical studies of 5-HT function using I.V. l-Tryptophan. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1990, 14, 459-472.	2.5	27
87	After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression. Journal of Affective Disorders, 1990, 18, 167-175.	2.0	47
88	Lithium Treatment and Serotoninergic Function. Archives of General Psychiatry, 1989, 46, 13.	13.8	86
89	Neuroendocrine and Mood Responses to Intravenous L-Tryptophan in 3,4-Methylenedioxymethamphetamine (MDMA) Users. Archives of General Psychiatry, 1989, 46, 20.	13.8	90
90	Effects of Desipramine and Fluvoxamine Treatment on the Prolactin Response to Tryptophan. Archives of General Psychiatry, 1989, 46, 625.	13.8	70

#	Article	IF	CITATIONS
91	Effects of trazodone treatment on serotonergic function in depressed patients. Psychiatry Research, 1988, 24, 165-175.	1.7	19
92	Efficacy of fluvoxamine in treatment-refractory depression. Journal of Affective Disorders, 1988, 15, 55-60.	2.0	64
93	Effects of trazodone treatment on alpha-2 adrenoceptor function in depressed patients. Psychopharmacology, 1986, 89, 38-44.	1.5	20
94	Effects of tranylcypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients. Life Sciences, 1985, 37, 809-818.	2.0	36
95	Noradrenergic function and the cortisol response to dexamethasone in depression. Psychiatry Research, 1985, 15, 5-15.	1.7	67